Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 4/20 | 0.33 |
| ▸ | PLAU | P00749 | 4/20 | 0.33 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.32 |
| ▸ | DNM1L | O00429 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019284 | 0.91 | DNM1L (0.35) | RORCHRH3PLGPLAUF10 | |
| SCHEMBL3012900 | 0.91 | DNM1L (0.37) | KMT2AHRH3PLGPLAULMNA | |
| SCHEMBL3007526 | 0.89 | MAPT (0.39) | KMT2ALMNATSHRALDH1A1 | |
| SCHEMBL3011506 | 0.87 | ALDH1A1 (0.34) | FABP4KMT2AHRH3LMNADNM1L | |
| SCHEMBL3655255 | 0.87 | FABP4 (0.42) | FABP4KMT2APLGPLAUF10 | |
| SCHEMBL3007229 | 0.87 | ALDH1A1 (0.34) | FABP4HRH3DNM1LOGAALDH1A1 | |
| SCHEMBL3006880 | 0.86 | OGA (0.36) | FABP4KMT2AHRH3LMNADNM1L | |
| SCHEMBL3016738 | 0.86 | SMN1; SMN2 (0.36) | KMT2AHRH3DNM1LOGAALDH1A1 | |
| SCHEMBL3014593 | 0.86 | CACNA1G (0.42) | FABP4HRH3LMNADNM1LOGA | |
| SCHEMBL3004517 | 0.86 | LMNA (0.37) | FABP4HRH3LMNADNM1LOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | FABP4 3254/4885RORC 2757/4885KMT2A 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.